Antimicrobial Photodynamic Therapy in the Treatment of Oral Erythematous Candidiasis: a Controlled and Randomized Clinical Trial
Overview
Authors
Affiliations
Objective: To analyze the clinical and microbiological efficacy of antimicrobial photodynamic therapy (aPDT) in patients with erythematous candidiasis (EC).
Methods: This study was a controlled and randomized clinical trial in patients diagnosed with EC, who were allocated into a control group (CG) and experimental group (EG) treated with nystatin oral suspension and aPDT with methylene blue 0.1%, respectively. A clinical index was used to classify the EC lesions from mild to severe and assess the treatment efficacy. Microbiological samples were collected before and after aPDT session and analyzed by counting colony-forming units (CFUs) of Candida and Staphylococcus sp.
Results: A total of 41 patients (CG (n = 18); EG (n = 23)) were analyzed in our research. Of these, 16 (94.1%) of the CG and 16 (84.2%) of the EG exhibited complete remission of the lesions. Regarding the degree of the lesion, it was observed that the severe lesions were more difficult to present remission, while all the mild and moderate lesions showed complete regression (p = 0.001). The microbiological analysis showed that Candida albicans and Staphylococcus sp. were the most prevalent microorganisms, and the aPDT group showed a decrease in CFUs of these microorganisms after the first aPDT session (p < 0.05).
Conclusions: aPDT proved to be a clinically and microbiologically effective therapy for treating EC.
Trial Registration: Registered at ClinicalTrials.gov; Set 12th, 2019; No. RBR-8w8599.
Clinical Relevance: aPDT is a promising alternative treatment since it presents satisfactory results and does not cause damage to oral tissues or develop resistance to the treatment.
Pitaksanurat P, Mayeah N, Saithong P, Pimha S, Sirikarn P, Damrongrungruang T J Oral Microbiol. 2024; 16(1):2369357.
PMID: 38903483 PMC: 11188948. DOI: 10.1080/20002297.2024.2369357.